Abstract:Cisplatin-based chemotherapy is the current standard care for lung cancer patients; however, drug resistance frequently develops during treatment, thereby limiting therapeutic efficacy.The molecular mechanisms underlying cisplatin resistance remain elusive. In this study, we conducted an analysis of microarray data from the Gene Expression Omnibus (GEO) database under the accession numbers GSE21656, which encompassed expression profiling of cisplatin-resistant H460 (DDP-H460)and the parental cells (H460). Subsequently, we calculated the differentially expressed genes (DEGs) between DDP-H460 and H460. Gene Ontology (GO) enrichment analysis and Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway analysis of DEGs demonstrated significant impact on the Rap1, PI3K/AKT and MAPK signaling pathways. Moreover, protein and protein interaction (PPI) network analysis identified PRKCA, DET1, and UBE2N as hub genes that potentially contribute predominantly to cisplatin resistance. Ultimately, PRKCA was selected for validation due to its significant prognostic effect, which predicts unfavorable overall survival and disease-free survival in patients with lung cancer. Network analysis conducted on The Cancer Genome Atlas (TCGA) database revealed a strong gene-level correlation between PRKCA and TP53, CDKN2A, BYR2, TTN, KRAS, and PIK3CA; whereas at the protein level, it exhibited a high correlation with EGFR, Lck, Bcl2, and Syk. The in vitro experiments revealed that PRKCA was upregulated in the cisplatin-resistant A549 cells (DDP-A549), while knockdown of PRKCA increased DDP-A549 apoptosis upon cisplatin treatment. Moreover, we observed that PRKCA knockdown attenuated DDP-A549 proliferation, migration and invasion ability. Western blot analysis demonstrated that PRKCA knockdown downregulated phosphorylation of PI3K expression while upregulated the genes involved in ferroptosis signaling. In summary, our results elucidate the role of PRKCA in acquiring resistance to cisplatin and underscore its potential as a therapeutic target for cisplatin-resistant lung cancer.

Acquired cisplatin resistance in the head-neck cancer cell line Cal27 is associated with decreased DKK1 expression and can partially be reversed by overexpression of DKK1

DKK1 is a potential novel mediator of cisplatin-refractoriness in non-small cell lung cancer cell lines

Dickkopf-3 (Dkk3) induces apoptosis in cisplatin-resistant lung adenocarcinoma cells via the Wnt/β-catenin pathway.

DKK1 Promotes Epithelial–Mesenchymal Transition and Cisplatin Resistance in Gastric Cancer via Activation of the PI3K/AKT Pathway

Dickkopf-1 expression is repressed by oncogenic human papillomaviruses (HPVs) and regulates the Cisplatin sensitivity of HPV-positive cancer cells in a JNK-dependent manner

DKK1 as a chemoresistant protein modulates oxaliplatin responses in colorectal cancer

DKK1 Affects Survival of Patients with Head and Neck Squamous Cell Carcinoma by Inducing Resistance to Radiotherapy and Immunotherapy

Identification of Genes Associated with Cisplatin Resistance in Human Oral Squamous Cell Carcinoma Cell Line

DKK4 Enhances Resistance to Chemotherapeutics 5-Fu and YN968D1 in Colorectal Cancer Cells.

The Interaction Between PDCD4 and YB1 is Critical for Cervical Cancer Stemness and Cisplatin Resistance.

Reduced Cisplatin Sensitivity Of Head And Neck Squamous Cell Carcinoma Cell Lines Correlates With Mutations Affecting The Cooh-Terminal Nuclear Localization Signal Of P53

A Genome Wide CRISPR Profiling Approach Identifies Mechanisms of Cisplatin Resistance in Head and Neck Squamous Cell Carcinoma.

Elevated DKK1 Expression is an Independent Unfavorable Prognostic Indicator of Survival in Head and Neck Squamous Cell Carcinoma

DKK4 is Important in Snail1-induced Chemoresistance to Fluorouracil in Colorectal Cancer

Transcriptome analysis reveals PRKCA as a potential therapeutic target for overcoming cisplatin resistance in lung cancer through ferroptosis

Integrated Analysis of DNA Methylation and Mrna Expression Profiling Reveals Candidate Genes Associated with Cisplatin Resistance in Non-Small Cell Lung Cancer.

RecQ protein‐like 4 drives cisplatin chemosensitivity of cervical cancer cells by modulating annexin A2

Cisplatin pretreatment enhances the antitumor activity of cytokine-induced killer cells in a T cell-dependent manner

Antisense oligodeoxynucleotide targeting chk1 increases sensitivity of HeLa cells to apoptosis induced by DDP

The Noncoding RNA Expression Profile and the Effect of Lncrna AK126698 on Cisplatin Resistance in Non-Small-cell Lung Cancer Cell.

Inhibition of the colony-stimulating-factor-1 receptor affects the resistance of lung cancer cells to cisplatin